Inteligex is developing innovative stem cell and drug-based therapies for traumatic spinal cord injury.

Traumatic spinal cord injuries can have devastating long-term physical, social, and financial impacts on patients and their families. Currently, there are no effective drug or regenerative therapies available for the millions of people living with this condition.

Inteligex’s mission is to bring to market the first effective regenerative treatment for spinal cord injury and to be the leading personalized regenerative medicine company for the treatment of SCI and other diseases of the central nervous system.

Inteligex’s regenerative platform is also being optimized for other conditions impacting the central nervous system, including cerebral palsy, stroke, multiple sclerosis, and amyotrophic lateral sclerosis.